EP2089419A2 - INHIBITION D'UNE AGRÉGATION DE BETA-AMYLOïDE - Google Patents

INHIBITION D'UNE AGRÉGATION DE BETA-AMYLOïDE

Info

Publication number
EP2089419A2
EP2089419A2 EP07824323A EP07824323A EP2089419A2 EP 2089419 A2 EP2089419 A2 EP 2089419A2 EP 07824323 A EP07824323 A EP 07824323A EP 07824323 A EP07824323 A EP 07824323A EP 2089419 A2 EP2089419 A2 EP 2089419A2
Authority
EP
European Patent Office
Prior art keywords
lys
val
leu
vai
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07824323A
Other languages
German (de)
English (en)
Inventor
Jesus Zurdo
Susan Fowler
Ernest Giralt
Meritxell Teixido
Natalia Carulla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zapaloid Ltd
Original Assignee
Zapaloid Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zapaloid Ltd filed Critical Zapaloid Ltd
Publication of EP2089419A2 publication Critical patent/EP2089419A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Definitions

  • This invention relates to the inhibition of protein aggregation, in particular the inhibition of A ⁇ 1-42 aggregation. This may be useful, for example, in the treatment of Alzheimer's disease
  • AD Alzheimer's disease
  • AP 1-42 beta amyloid peptide
  • a ⁇ 1-42 consists of residues 673 to 713 of the amyloid precursor protein (APP: NCBI Gene ID 351; P05067; NP_000475.l Gl: 4502167) .
  • Methods of reducing the amount or toxicity of these aggregates would be useful in the treatment of AD and other diseases related to the deposition of A ⁇ 1-42 such as cerebral amyloid angiopathy (CAA) and inclusion-body myositis (IBM) .
  • CAA cerebral amyloid angiopathy
  • IBM inclusion-body myositis
  • the present inventors have identified peptides which inhibit the aggregation of the A ⁇ 1-42 peptide and may therefore be useful in the treatment of Alzheimer's disease
  • One aspect of the invention provides a peptide consisting of four to ten D-amino acids having the reverse sequence of a contiguous amino acid sequence within the region between residues 16 and 42 of A ⁇ 1-42 .
  • a peptide described herein may inhibit the aggregation of A ⁇ 1-42 and may, for example, consist of 4, 5, 6, I 1 8, 9 or 10 D-amino acids, preferably 6, 7 or 8 D-amino acids.
  • a peptide may consist of four to ten D-amino acids having the reverse sequence of a contiguous amino acid sequence in the region between residues 16-42 of A ⁇ i-42 .
  • the D-amino acid sequence in the N terminal to C terminal direction corresponds to the contiguous amino acid sequence of A ⁇ 1-42 in the C terminal to N terminal direction.
  • a D-amino acid sequence which is the reverse of an L-amino acid sequence is commonly known as a 'retroenantiomer' of that sequence.
  • a peptide may consist of the reverse sequence of a contiguous amino acid sequence which comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, or all the residues from a region selected from the group consisting of residues 16-22, residues 30-36, residues 32-38, residues 34-40 and residues 36-42 of A ⁇ i -42 .
  • a peptide may consist of a sequence of D-amino acids selected from the group consisting of: eaffvlk, vmlgiia, wggvml, ggvmlgi and aiwggv.
  • Peptides of the invention also encompass sequences which consist of an amino acid sequence set out herein with 1, 2, 3 or 4 D-amino acids added, deleted or substituted.
  • 1, 2, 3 or 4 D-amino acids may be added or deleted from the N-terminal or C-terminal of a peptide sequence set out herein.
  • the 1, 2, 3 or 4 additional D-amino acids which are added to a peptide set out herein may be the reverse sequence of amino acids which adjoin the N-terminal or C-terminal of the contiguous sequence in A ⁇ . 42 .
  • the 1, 2, 3 or 4 additional D-amino acids may be residues which are not the reverse sequence of amino acids which adjoin the N-terminal or C-terminal of the contiguous sequence in Ap 1-42 (i.e. they may be heterologous amino acids) .
  • one or more N-methyl-phenylalanine residues may be added to the N terminal, as described below, to facilitate transport across the blood brain barrier.
  • a substitution may be a conservative or non-conservative substitution.
  • a peptide may consist of sequences having one, two, three or more conservative or non-conservative substitutions relative to a sequence set out herein.
  • a conservative substitution is a replacement of a D-amino acid residue with another of similar properties, such as charge, polarity and/or hydrophobicity.
  • conservative substitutes for an amino acid within the native polypeptide sequence can be selected from other members of the class to which the amino acid belongs .
  • Amino acids can be divided into the following four groups: (1) acidic amino acids, (2) basic amino acids, (3) neutral polar amino acids, and (4) neutral, nonpolar amino acids.
  • amino acids within these various groups include, but are not limited to, (1) acidic (negatively charged) amino acids such as aspartic acid and glutamic acid; (2) basic (positively charged) amino acids such as arginine, histidine, and lysine; (3) neutral polar amino acids such as glycine, serine, threonine, cysteine, cystine, tyrosine, asparagine, and glutamine; and (4) neutral nonpolar (hydrophobic) amino acids such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.
  • Conservative substitution tables listing functionally similar amino acids are known in the art (Altschul, S. F.
  • peptide consisting of a sequence having one, two, three or more conservative substitutions may show 95%, 99% or 100% sequence similarity to a sequence set out herein.
  • Amino acid similarity may be defined with reference to the algorithm GAP (Accelerys) , or the TBLASTN program, of Altschul et al . (1990) J. MoI. Biol. 215: 403- 10.
  • a peptide may consist of a sequence of D-amino acids in the reverse sequence of a contiguous amino acid sequence in the region between residues 16-42 of A ⁇ ! _ 42 , with one, two, three or more substitutions which reduce or prevent beta strand association.
  • one or more, 2 or more, 3 or more or 4 D-amino acids in a sequence set out herein may be replaced by D-proline.
  • the residue at position 2 and/or position 3 may be replaced by D-proline.
  • peptides include peptides consisting of a D-amino acid sequence selected from the group consisting of: epffvlk, eapfvlk, vplgiia, vmpgiia, vpggvml, wpgvml , gpvmlgi, ggpmlgi, apwggv, and aipvggv (where lower case letters denote D amino acids) .
  • Suitable peptides include ZP-0281 to ZP-0307, as set out in table 1.
  • Another aspect of the invention provides a peptide consisting of three to six D-amino acids, wherein said peptide comprises one more charged residues at both the N and C termini, and one or more central residues between said charged residues, wherein the one or more central residues comprise a hydrophobic residue.
  • Charged residues may be selected from the group consisting of lysine (K) , histidine (H) , arginine (R) , aspartic acid (D) , glutamic acid (E) and any non naturally occurring amino acids that contain a charge .
  • the N terminal residues may be positively charged residues, such as R or K, and the C terminal residues may be negatively charged residues such as D or E.
  • the one or more charged residues at the N terminal have a different charge from the one or more charged residues at the C terminal.
  • the charged residue at the N terminus of the peptide may be R or K and the charged residue at the C terminus may be D or E or vice versa.
  • the central region preferably comprises one to three residues.
  • Hydrophobic residues may be selected from the group consisting of tryptophan (W) , phenylalanine (F) , leucine (L) , isoleucine (I) , valine (V) and methionine (M) or any non-naturally occurring amino acids that are hydrophobic in nature.
  • the central region may further comprise one or more residues selected from the group consisting of glycine (G) , alanine (A) , serine (S) and isoleucine (I) which act as spacers between the charged and hydrophobic amino acids.
  • G glycine
  • A alanine
  • S serine
  • I isoleucine
  • the central region consists of a sequence selected from the group consisting of GWG, GFG, SWS, SFS, AWA, GWI, SWI, two amino acid fragments of any of these, W and F.
  • suitable peptides include peptides selected from the group consisting of kgwge rgwge, kgwgd, rgwgd, kgwe, kwge, kwe, kgfge, rgfge, kgfgd, rgfgd, kgfe, kfge, kfe, kswse, rswse, kswsd, rswsd, kswe, kwse, ksfse, rsfse, ksfsd, rsfsd, ksfe, kfse, kawae, rawad, kgwge, rgwge, kgwgd, rgwgd, kgfge, rgfge, kgfgd, rgfgd, kswse, kswsd, rswsd, ksfse, ksfse,
  • 1, 2, 3 or 4 D-amino acids may be added to the N-terminal and/or C-terminal of a peptide sequence set out herein.
  • one or more N-methyl-phenylalanine residues may be added to the N terminal, as described below, to facilitate transport across the blood brain barrier.
  • Peptides of the invention also encompass sequences which consist of a sequence set out herein with 1, 2, 3 or 4 modified D-amino acids.
  • D-amino acids in peptides described herein may be modified, for example by the introduction of a substituent chemical group, for example at the N position.
  • Suitable substituent groups include halogens such as F, nitrate, and alkyl groups, such as methyl or acetyl.
  • Peptides of the invention may contain one or more substitutions at any position in the sequence with a non natural D or L amino acid.
  • D-Cha D-cyclohexane D-alanine
  • D-homophenylalanine D- HomoPhe
  • D-Napthylalanine D-NaIl
  • D-2-Napthylalanine D-Nal2
  • D- 2-pyridyalanine D-PyrAla
  • 4-fluoro-D phenylalanine D-pFPhe
  • 1, 2 , 3 4-D-tetrahydroisoquinoline-3-carboxylic acid
  • D-Tic 5-phenyl- pyrolidine-2-carboxylic acid(D-2R, 5S)
  • 4-nitro-D-phenylalanine D- pNO2Phe
  • 3(3,4 dihydroxyphenyl) D-alanine D-DOPA
  • An amino acid modification may reduce or prevent beta strand association.
  • one or more, for example 2, 3 or 4 D-amino acids in the peptide sequence may be N- substituted, preferably N- alkylated, for example N-methylated or N acetylated.
  • Examples of peptides comprising modified or non-naturally occurring amino acids include compounds ZP-0387 to ZP-0398 and ZP-0602 to ZP- 0607, as shown in Table 1. These are modified retroenantiomers .
  • Anther aspect of the invention provides a peptide consisting of four to ten D-amino acids, which forms a beta sheet interaction with at least part of an aggregation region in A ⁇ 1-42 .
  • the peptide preferably consists of a sequence which is neither the forward or reverse sequence of Ap 1-42 (i.e. a heterologous sequence) which has been designed to specifically interact with at least part of an aggregation region in A ⁇ 1-42 .
  • Suitable peptides may be designed using the in silico techniques described in US601821553.
  • the sequence of the peptide may be further optimised to maximise interaction with A ⁇ 1-42 using energy minimisation routines.
  • Peptides designed using this strategy include ZP-308 to ZP-0316, ZP- 407 and ZP-0671 to ZP-0716 (Table 1) .
  • D-amino acid peptides such as retroenantiomers, may be produced by employing D- form derivatized amino acid residues in the chemical synthesis.
  • Suitable D-amino acids for solid phase peptide synthesis are commercially available (e.g., Advanced Chem Tech, Louisville; Nova Biochem, San Diego; Sigma, St Louis,- Bachem California Inc., Torrance, etc.) .
  • the peptides can be readily prepared, for example, according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J. M. Stewart and J. D.
  • Peptides and oligopeptides comprising peptides as described above are also provided as aspects of the present invention, particularly wherein the peptide is fused to one or more sequences which do not correspond to the forward or reverse sequence of A ⁇ 1-42 , such as retro-enantiomeric sequences (i.e. heterologous sequences) .
  • heterologous is meant from a different source to the sequence in question, for example, when the peptide is a retro-enantiomer of a natural A ⁇ i_ 42 sequence, a heterologous sequence is a sequence other than a retro-enantiomer of the natural A ⁇ i -42 sequence joined by a peptide bond without intervening amino acids to the contiguous A ⁇ 1 . i2 sequence described herein.
  • heterologous amino acids are fused to the peptide, the whole contiguous sequence of amino acids does not occur within beta- A ⁇ 1-42 , and may be 10 or more, preferably 15 or more, more preferably 20 or more, 25 or more or 30 or more amino acids.
  • Heterologous sequences of amino acids which may be fused to a peptide described herein may include antibodies or antibody fragments, such as Fabs, F(ab') 2 s / dAbs, Fvs, and scFvs, neurotrophins such as NGF BDNF, NT3 , and GDNF, Insulin-like Growth Factors, such as IGFl and IGF2 , transferrin and other peptides that bind to the transferrin receptor, and other coupling partners involved in BBB transport, as described herein.
  • antibodies or antibody fragments such as Fabs, F(ab') 2 s / dAbs, Fvs, and scFvs
  • neurotrophins such as NGF BDNF, NT3 , and GDNF
  • Insulin-like Growth Factors such as IGFl and IGF2
  • transferrin and other peptides that bind to the transferrin receptor and other coupling partners involved in BBB
  • Peptides and oligopeptides as described herein may be N-terminal and/or C-terminal modified, for example by addition of a coupling partner or moiety.
  • Coupling partners which may be linked to a peptide may include protecting groups or pegylation for example to help to increase the half-life of the peptide in vivo, and targeting groups . Suitable protecting groups are well-known in the art (e.g., Greene e al . , (1991) Protective Groups in Organic Synthesis, 2nd ed. , John Wiley & Sons, Inc.
  • an acetyl group may be used to protect the amino terminus and/or an amide group may be used to protect the carboxyl terminus.
  • Acetylation may, for example, be accomplished during the synthesis when the peptide is on the resin using acetic anhydride.
  • Amide protection may, for example, be achieved by the selection of a proper resin for the synthesis.
  • BBB transport moieties which may, for example be attached to the N or C terminal of the peptide sequence.
  • a Blood Brain Barrier (BBB) transport moiety may include moieties which facilitate passive diffusion across the BBB and moieties that interact with a receptor or carrier and cross the BBB by receptor or carrier mediated endocytosis, such as Sweet Arrow Peptide (SAP) (Fernandez-Carneado et al Angew Chem Int Ed Engl 2004 43 14 1811-1814), retroviral TAT protein (C. Foerg et al Biochemistry 2005 44 72) , transferrin and transferrin receptor binding peptides.
  • SAP Sweet Arrow Peptide
  • C. Foerg et al Biochemistry 2005 44 72 retroviral TAT protein
  • Suitable Blood Brain Barrier (BBB) transport moieties include L or D N-methyl phenylalanine (NMePhe) which has been shown to enhance transport across the BBB (Conradi, R. A. et al Pharm. Res. (1992) 9, 435-439; Chikhale, E. G. et al Pharm. Res. 1994, 11, 412-419; Chikhale, E. G. et al J. Pharmacol. Exp. Ther. (1995) 273, 298-303), transferrin, IGFl, IGF2 and leptin.
  • Peptides may be synthesised with one or more, for example 1, 2, 3 or 4 N-methyl phenylalanine residues using standard synthesis techniques. See example ZP-0387 to ZP-0398, ZP-0602, ZP-0603, ZP- 0606 and ZP-0607 in table 1
  • a compound comprising a peptide as described herein linked to one or more coupling partners is provided by another aspect of the invention.
  • a peptide or compound as described herein may be used in a method of treatment of the human or animal body, for example for use in the treatment of Alzheimer's Disease, or in the manufacture of a medicament for the treatment of Alzheimer's Disease and other diseases related to the deposition of Ap 1-42 such as cerebral amyloid angiopathy
  • a method of treatment of Alzheimer's disease or other disease characterised by the deposition of Ap 1-42 may comprise; administering a peptide as described herein as described herein to an individual in need thereof .
  • Administration of a peptide or compound described herein is preferably in a "prophylactically effective amount” or a “therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual.
  • the actual amount administered, and rate and time-course of administration will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors.
  • a peptide or compound as described herein described herein may be administered as a pharmaceutical composition.
  • a pharmaceutical composition may include, in addition to the peptide or compound, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the precise nature of the carrier or other material will depend on the route of administration, which may be oral, nasal or by injection, e.g. cutaneous, subcutaneous or intravenous.
  • Another aspect of the invention provides a method of producing a pharmaceutical composition, for example for use in treating Alzheimer's disease or other disease characterised by the deposition of APi -42 , comprising; admixing a peptide or compound described herein or exemplified in Table 1 with a pharmaceutically acceptable excipient, carrier, buffer or stabiliser.
  • compositions for oral administration may be in tablet, capsule, powder or liquid form.
  • a tablet may include a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
  • compositions suitable for nasal administration include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser include aqueous or oily solutions of the active compound.
  • the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen- free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen- free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, or Lactated Ringer's Injection.
  • Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
  • compositions comprising a peptide or compound described herein may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • the invention encompasses each and every combination and sub- combination of the features that are described above.
  • Figure 1 shows the inhibition of A ⁇ 1-42 aggregation by a selection of inhibitors from the group ZP-0326-ZP-0375.
  • Figure 2 shows the inhibition of A ⁇ 1-42 aggregation by inhibitors designed to interact with the C-terminal region of A ⁇ l-42.
  • Figure 3 shows the inhibition of A ⁇ i -42 aggregation by variants of ZP-0312 with BBB translocation and cell internalisation moieties at the N-terminus.
  • Figure 4 shows the inhibition of A ⁇ i -42 aggregation by inhibitors with one NMePhe substitution at position 2 in the sequence.
  • Figure 5 shows the inhibition of A ⁇ l-42 mediated toxicity for compounds ZP-0336, ZP-0305 and ZP-0312.
  • Figure 6 shows a reduction in A ⁇ l-42 aggregation related toxicity for compounds ZP-0387 and ZP-0391.
  • Table 1 shows examples of A ⁇ 1-42 aggregation inhibitors in accordance with the invention.
  • L and D amino acids are denoted by their prefix.
  • (Ac) denotes acetylation and NMePhe denotes N-methyl phenylalanine.
  • Table 2 shows the chemical structures of the non-naturally occurring amino acids used in inhibitor synthesis
  • SEQ ID NO: 1 shows the amino acid sequence of A ⁇ 1-42 .
  • SHSY5Y cells were seeded overnight on a 96 well plate at 2 x 10 4 cells per well. Cells were then put in 200 ⁇ l serum free media and A ⁇ 1-42 was added to a final concentration of 10 ⁇ M. Inhibitor was added at various concentrations. Plates were incubated at 37 0 C with 5% C02 and toxicity levels due to A ⁇ l-42 aggregation were assessed after 24 and 48 hours using the LDH (CytoTox-One Homogeneous Membrane Integrity Assay - Promega) and MTS (CellTiter 96 Aqueous One Solution Cell Proliferation Assay - Promega) assays.
  • LDH CytoTox-One Homogeneous Membrane Integrity Assay - Promega
  • MTS CellTiter 96 Aqueous One Solution Cell Proliferation Assay - Promega
  • Figure 1 shows inhibition of A ⁇ l-42 aggregation by a selection of inhibitors from the group ZP-0326-ZP-0375. In this case the inhibitor was added at a 20 fold molar excess. Inhibition was indicated by the resulting reduction in rate of aggregation and reduction in endpoint Thioflavin T (ThT) fluorescence.
  • Figure 2 shows inhibition of A ⁇ l-42 aggregation mediated by inhibitors ZP- 0305 and ZP-0312. A ⁇ l-42.
  • ZP-0305 is an example of a 7 residue peptide designed to inhibit aggregation of A ⁇ l-42 and ZP-0312 is an example of a 5 residue peptide designed using Zyentia's technology to optimise the interaction of the inhibitor with A ⁇ l-42. In both cases inhibition is apparent as an increase in lag phase and a reduction in rate of aggregation and final ThT fluorescence. The level of inhibition is dose dependant and these inhibitors are active at concentrations lower than that of A ⁇ l-42 in the reaction.
  • Figure 3 shows inhibition of A ⁇ l-42 by variants of ZP-0312 with BBB translocation and cell internalisation moieties at the N-terminus.
  • ZP-0402 has 4 NMePhe residues and ZP-0609 has L-DOPA at the N- terminus . This shows that even with these moieties present the inhibitor is still active.
  • ZP-0402 shows dose dependant inhibition as demonstrated by the increase in lag phase with increasing concentration of compound. In the presence of ZP-0609 aggregation is entirely inhibited in the timeframe of the observation.
  • Figure 4 shows inhibition of A ⁇ l-42 aggregation in the presence of inhibitors from the series with one NMePhe substitution at position 2 in the sequence.
  • ZP- 0387 and ZP- 0391 are shown representative of the series ZP-0387-ZP-0398 which contain a non natural amino acid substitution at position 3 in the inhibitor sequence.
  • the data show that for ZP- 0387 and ZP-0391 inhibition is observed at sub equimolar ratios and at in some cases abolished completely in the timeframe of the observation.
  • Figure 5 shows inhibition of A ⁇ l-42 mediated toxicity for compounds
  • the final concentration of A ⁇ l-42 was 10 ⁇ M and ZP-0305 and ZP-0312 are also at a final concentration of 10 ⁇ M.
  • ZP-0336 was added at a 5 fold molar excess.
  • cell viability is increased by >30%.
  • Figure 6 shows cell viability for compounds ZP- 0387 and ZP-0391.
  • inhibitor was added at a final concentration of 10 ⁇ M.
  • a dramatic increase in viability after 48h is seen with all inhibitors compared to Ap 1-42 alone indicating that they are very effective in preventing aggregation mediated toxicity.
  • the inhibitor alone was added to the cells as a control . None of the compounds showed any toxicity at the concentrations tested.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne les inhibiteurs peptidyliques d'une agrégation de ABeta1-42. Ces inhibiteurs peuvent être utiles, par exemple, dans le traitement de la maladie d'Alzheimer.
EP07824323A 2006-10-27 2007-10-26 INHIBITION D'UNE AGRÉGATION DE BETA-AMYLOïDE Withdrawn EP2089419A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85469406P 2006-10-27 2006-10-27
PCT/GB2007/004079 WO2008050133A2 (fr) 2006-10-27 2007-10-26 Inhibition d'une agrégation de beta-amyloïde

Publications (1)

Publication Number Publication Date
EP2089419A2 true EP2089419A2 (fr) 2009-08-19

Family

ID=38962885

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07824323A Withdrawn EP2089419A2 (fr) 2006-10-27 2007-10-26 INHIBITION D'UNE AGRÉGATION DE BETA-AMYLOïDE

Country Status (2)

Country Link
EP (1) EP2089419A2 (fr)
WO (1) WO2008050133A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2646470T (pt) 2010-11-30 2017-05-03 Hoffmann La Roche Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica
US9475840B2 (en) 2012-02-27 2016-10-25 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
HU231182B1 (hu) * 2013-05-17 2021-08-30 Szegedi Tudományegyetem A ß-amiloid toxicitását gátló kis peptid inhibitorok
EP3035969B1 (fr) 2013-08-19 2022-08-03 S.M. Discovery Holdings Inc. Composition de nanoadministration peptidique ciblant deux récepteurs
GB201414038D0 (en) * 2014-08-07 2014-09-24 Univ Sussex The Alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69733655T2 (de) * 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
EP1173480B1 (fr) * 1999-05-05 2008-01-16 Neurochem (International) Limited Peptides stereoselectifs antifibrillogenes
AU2002327514A1 (en) * 2001-08-23 2003-03-10 Stanley Stein Application of peptide conjugates to alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008050133A3 *

Also Published As

Publication number Publication date
WO2008050133A2 (fr) 2008-05-02
WO2008050133A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
ES2438779T3 (es) Péptidos administrados oralmente para mejorar aterosclerosis
CA2400410C (fr) Composes antimicrobiens et preparations
KR102314231B1 (ko) 전립선 암 치료용 조성물
JP2009542611A (ja) アルファ−シヌクレイン凝集の阻害
KR20190016026A (ko) 프로그램 된 세포사멸을 유도하는 cd47의 효능제 및 이의 프로그램 된 세포사멸 결함과 관련된 질병 치료에의 용도
US11229678B2 (en) Neuroprotective peptides
JP5913982B2 (ja) 抗腫瘍活性を有するノナペプチド
AU2001237616A1 (en) Antimicrobial compounds and formulations
EP2089419A2 (fr) INHIBITION D'UNE AGRÉGATION DE BETA-AMYLOïDE
US20220105150A1 (en) Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens
EP3887390A1 (fr) Agents de liaison à dpep-1 et leurs méthodes d'utilisation
AU2015218198B2 (en) Peptides that block leukocyte recruitment and methods of use
US20200071357A1 (en) Antimicrobial peptides
US20050245451A1 (en) Peptides selectively lethal to malignant and transformed mammalian cells
KR102397510B1 (ko) 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
KR102166543B1 (ko) 켈로이드 억제용 조성물 및 그 억제 방법
Hilchie et al. Obstacles and solutions to the use of cationic antimicrobial peptides in the treatment of cancer
CA2553436A1 (fr) Peptides selectivement letaux pour des cellules mammiferes transformees et malignes
KR20160140147A (ko) 심장 허혈후 재관류 손상에 의한 심장 질환 치료 및 예방용 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090527

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20091125

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100407